Johnson & Johnson, Abbott, and Boston Scientific Unveil Q2 2026 Results: Cardiovascular Innovation, CGM Leadership, and Strategic Acquisitions Drive Future Growth

Its Q2 revenue reached237Billion USD (+5.8%), ProfitRecently55Billion USD (+18.2%), including the medical device businessQ2 Revenue8$500 million（+7.3%）；

Performance of Equipment Segmentation Business:

• Cardiovascular Business: $2.313 billion (+23.5%)

• Orthopedic Business: $2.305 billion (+0.3%)

• Ophthalmology Business:$13.69 billion (+6.5%)

• Surgical Business: $2.555 billion (+2.7%)

It is clear that the cardiovascular business has become the true driving force behind Johnson & Johnson's (Medical Devices) growth.The strong performance of the cardiovascular business can be attributed to the layout (acquisitions) in previous years.Abiomed, ShockWave, and the acceleration of PFA development). When it comes to the cardiovascular business alone, Johnson & Johnson is in no way inferior to Boston Scientific, which is currently gaining significant momentum.

However, other business segments of Johnson & Johnson performed disappointingly, with growth being too slow. LikeOrthopedic business grew only 0.3%, while the largest business segmentSurgical business growth rate is only 2.7%. The main reason for the slow growth of the company's business segments is that Johnson & Johnson missed the robotics era, whether in orthopedics or surgery. Although orthopedics has introduced surgical robots, it still lags far behind Stryker. Moreover, the surgical robotics in the surgical business...Ottava is still in clinical trials and will not be able to submit a registration application to the FDA until 2026.

Its Q2 revenue reached$11.1 billion (+7.4%), profit$2.21 billion. Including the medical device businessQ2 Revenue53.69Billion US dollars（+13.4%）, It's AbbottGrowthMain Power Source.

Growth in Medical Device BusinessThe main drivers were diabetes care, heart failure treatment, structural heart disease, and electrophysiology. Key contributing products included the FreeStyle Libre continuous glucose monitor, Navitor (TAVR), and TriClip.TEER) and Aveir pacemaker. The star product remains the CGM, with sales reaching $1.9 billion this quarter, a year-over-year increase of 21.4%. The electrophysiology business also performed well, with sales reaching $700 million (an 11.5% year-over-year increase). The Volt PFA is key to Abbott's continued growth in the electrophysiology sector and will be crucial for Abbott's future success in this field.

Its Q2 revenue reached 50.6Billion USD (+22.8%), ProfitRecently7.97Billion US dollars (More than doubled from US$324 million in the same period last year）。

Seven of Boco's business segments achieved double-digit high growth, with three of them standing out. Particularly in the cardiac business andUrology Business, Growth Rate Nearly 30%.

• Cardiac Business: Revenue$26.47 billion (+29.3%）
• Peripheral Intervention Business:Revenue$6.98 billion (+18.3%)）
• Urology Business: Revenue$6.68 billion (+28.9%）
• Endoscopy Business:Revenue 7.37Billion USD (+9.1%)）
• Adjusted Business: Revenue 3.03Billion USD (+7.2%）

Boston Scientific's business is growing rapidly, benefitingYu Bokke's Insight in M&A: Achieving Astonishing Results with Minimal Investment.In the cardiovascular field, Boston Scientific acquires FARAPULSE (electrophysiology),Cortex (Electrophysiology), SoniVie (RDN), Bolt Medical (IVL),Silk Road Medical (Peripheral), etc.; acquisitions in the minimally invasive fieldAxonics (Neuromodulation), Intera Oncology (Interventional Oncology), etc. The maximum cost of these acquisitions does not exceed 4 billion US dollars. It can be said that Boston Scientific is a giant who truly knows how to spend money.

The Q2 performance of the three giants also reflects the strategic differences among the three companies. Both Boston Scientific and Johnson & Johnson have defined their cardiovascular businesses as the growth pivot for their future medical device businesses. From the first two quarters, Boston Scientific has risen to become the top in cardiovascular (USD 6.43 billion, +26.5%). Meanwhile, Johnson & Johnson has stabilized at fourth place (USD 4.416 billion, +20%; with a USD 1.5 billion gap from Edwards) and is closing the gap with Abbott (USD 5.974 billion, +9.1%). Based on the strong performances of Boston Scientific and Johnson & Johnson, the rankings of the top four players in the cardiovascular field are expected to undergo significant changes in the coming years.

In addition to the cardiovascular business, Johnson & Johnson is also betting on surgical robots, while Abbott continues to consolidate its dominance in the CGM field. Boston Scientific, on the other hand, is strengthening its position in the urology sector. Below are the core drivers of growth for the three giants in the future:

• Johnson & Johnson = Cardiovascular + Surgical Robotics

• Abbott = Continuous Glucose Monitoring + Electrophysiology + Leadless Pacemaker

• Boco = Pulse Field Ablation + Left Atrial Appendage Closure + Global Expansion